The Reversal of Drug-Resistance in Tumors Using a Drug-Carrying Nanoparticular System

Medical applications of nanoparticular systems have attracted considerable attention because of their potential use in therapeutic targeting of disease tissues and their lower level of toxicity against healthy tissue, relative to traditional pharmaceutical drugs. The use of nanoparticular systems has been shown to overcome the limitations of most anticancer drugs in clinical applications. In particular, the improved performance of smarted nanoparticular system for solving the drug resistance problems that typically interrupt tumor treatment has provided a promising strategy for successful tumor chemotherapy. This review highlights recent studies that have examined the therapeutic effect of nanoparticular systems on drug-resistant tumors and presents insight on how they work.

[1]  F. Sharom.  The P-glycoprotein multidrug transporter. , 2011, Essays in biochemistry.

[2]  You Han Bae,et al.  Recent progress in tumor pH targeting nanotechnology. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Eun Seong Lee,et al.  Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. , 2008, Small.

[4]  Ick Chan Kwon,et al.  Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Dongin Kim,et al.  A virus-mimetic nanogel vehicle. , 2008, Angewandte Chemie.

[6]  James R Heath,et al.  Nanotechnology and cancer. , 2008, Annual review of medicine.

[7]  Eun Seong Lee,et al.  Tumor pH-responsive flower-like micelles of poly(L-lactic acid)-b-poly(ethylene glycol)-b-poly(L-histidine). , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[8]  J. Au,et al.  Tumor Priming Enhances Delivery and Efficacy of Nanomedicines , 2007, Journal of Pharmacology and Experimental Therapeutics.

[9]  Xiaoling Fang,et al.  Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines. , 2007, International journal of pharmaceutics.

[10]  L. Fu,et al.  FG020326-loaded nanoparticle with PEG and PDLLA improved pharmacodynamics of reversing multidrug resistance in vitro and in vivo , 2007, Acta Pharmacologica Sinica.

[11]  Z. Duan,et al.  Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. , 2007, Cancer research.

[12]  Elizabeth Fox,et al.  Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor , 2007, Expert review of anticancer therapy.

[13]  Florian Obermeier,et al.  Cell-cell contacts prevent anoikis in primary human colonic epithelial cells. , 2007, Gastroenterology.

[14]  Hideyoshi Harashima,et al.  Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. , 2007, International journal of pharmaceutics.

[15]  Ruth Duncan,et al.  Polymer conjugates as anticancer nanomedicines , 2006, Nature Reviews Cancer.

[16]  Yang Wang,et al.  In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[17]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[18]  B. Brüne,et al.  Tumor hypoxia and cancer progression. , 2006, Cancer letters.

[19]  T. Ozben.  Mechanisms and strategies to overcome multiple drug resistance in cancer , 2006, FEBS letters.

[20]  Qiang Zhang,et al.  A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[21]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[22]  B. Goh,et al.  Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[23]  R. Advani,et al.  A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Gregory J. Downing,et al.  A cancer nanotechnology strategy , 2005 .

[25]  Pierre P Massion,et al.  Novel strategies for the early detection and prevention of lung cancer. , 2005, Seminars in oncology.

[26]  R. Kim,et al.  Recent advances in understanding the cell death pathways activated by anticancer therapy , 2005, Cancer.

[27]  You Han Bae,et al.  Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[28]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[29]  J. Fréchet,et al.  pH-Responsive copolymer assemblies for controlled release of doxorubicin. , 2005, Bioconjugate chemistry.

[30]  You Han Bae,et al.  Super pH-sensitive multifunctional polymeric micelle. , 2005, Nano letters.

[31]  C. Choi,et al.  ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal , 2005, Cancer Cell International.

[32]  D. Mahadevan,et al.  Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. , 2004, Blood.

[33]  K. Edwards,et al.  Effects of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymers on structure and stability of liposomal dioleoylphosphatidylethanolamine. , 2004, Journal of colloid and interface science.

[34]  N. Rapoport.  Combined cancer therapy by micellar-encapsulated drug and ultrasound. , 2004, International journal of pharmaceutics.

[35]  H. Fain,et al.  Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers. , 2004, Molecular pharmaceutics.

[36]  S. Dharap,et al.  Molecular targeting of drug delivery systems to cancer. , 2004, Current drug targets.

[37]  A. Kabanov,et al.  Fundamental Relationships Between the Composition of Pluronic Block Copolymers and Their Hypersensitization Effect in MDR Cancer Cells , 1999, Pharmaceutical Research.

[38]  J. Berenson,et al.  Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  T. Fojo,et al.  The role of ABC transporters in clinical practice. , 2003, The oncologist.

[40]  P. Couvreur,et al.  A computationally derived structural model of doxorubicin interacting with oligomeric polyalkylcyanoacrylate in nanoparticles. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[41]  You Han Bae,et al.  Polymeric micelle for tumor pH and folate-mediated targeting. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[42]  H. Coley,et al.  Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[43]  J. Parker.  Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein , 2003 .

[44]  Alexander V Kabanov,et al.  Pluronic block copolymers for overcoming drug resistance in cancer. , 2002, Advanced drug delivery reviews.

[45]  J. Simons,et al.  Hypoxia-directed cancer therapy , 2002 .

[46]  Gang Li,et al.  Cancer chemoresistance: The relationship between p53 and multidrug transporters , 2002, International journal of cancer.

[47]  Arnab Chakravarti,et al.  Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. , 2002, Cancer research.

[48]  J. Crawford.  Clinical uses of pegylated pharmaceuticals in oncology. , 2002, Cancer treatment reviews.

[49]  Alexander V Kabanov,et al.  Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. , 2002, Critical reviews in therapeutic drug carrier systems.

[50]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[51]  M. Gottesman.  Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[52]  W. Dalton,et al.  Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. , 2001, Molecular cancer therapeutics.

[53]  Gideon Rechavi,et al.  DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1 , 2001, Oncogene.

[54]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[55]  A. Rzhetsky,et al.  The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.

[56]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[57]  D. Tzemach,et al.  Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  Ralph Weissleder,et al.  Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells , 2000, Nature Biotechnology.

[59]  P Couvreur,et al.  Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. , 2000, Biomaterials.

[60]  M. Grever,et al.  Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. , 1999, Blood.

[61]  B. Masereel,et al.  P-glycoprotein inhibition by glibenclamide and related compounds , 1999, Pflügers Archiv.

[62]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[63]  W. Berger,et al.  Chemoresistance of Human Malignant Melanoma: Cellular and Molecular Aspects , 1998, Oncology Research and Treatment.

[64]  A. König,et al.  Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis , 1997, Leukemia.

[65]  A. Dantzig,et al.  Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. , 1996, Cancer research.

[66]  J. Hickman.  Apoptosis and chemotherapy resistance. , 1996, European journal of cancer.

[67]  D. Kerr,et al.  Clinical trials of P-glycoprotein reversal in solid tumours. , 1996, European journal of cancer.

[68]  R. Shoemaker,et al.  Overlapping phenotypes of multidrug resistance among panels of human cancer‐cell lines , 1996, International journal of cancer.

[69]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[70]  H. Clevers,et al.  The drug resistance-related protein LRP is the human major vault protein , 1995, Nature Medicine.

[71]  M. Evans,et al.  p53 modulation of TFIIH–associated nucleotide excision repair activity , 1995, Nature Genetics.

[72]  H. Hollema,et al.  Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  D. Fisher.  Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.

[74]  S. Simon,et al.  Cell biological mechanisms of multidrug resistance in tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[75]  C. Vergely,et al.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. , 1993, Cancer research.

[76]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[77]  H. Takano,et al.  Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. , 1990, Cancer research.